癌基因H-ras与抑癌基因P16在膀胱癌发生中关系的探讨  

Relationship of H-ras and P16 in Bladder Carcinoma

作　　者：郭萍[1] 许绍斌[2] 李泽惠[3] 章宗籍[1] 褚嘉佑[2] 

机构地区：[1]昆明医学院病理教研室,昆明650031 [2]中国医学科学院中国协和医科大学医学生物学研究所,昆明650118 [3]昆明医学院第二附属医院泌尿外科,昆明650101

出　　处：《昆明医学院学报》2004年第1期19-21,共3页Journal of Kunming Medical College

基　　金：云南省应用基础研究基金资助项目 (95C0 71M )

摘　　要：目的 :了解膀胱移行细胞癌中H -ras基因突变与P16抑癌基因缺失两者的关联 .方法 :应用PCR -SSCP银染和双重PCR对 31例膀胱移行细胞癌分别进行缺失和突变检测 .结果 :H -ras基因突变发生率为 38 7% ,P16抑癌基因缺失率为 2 2 6 % ,7例P16抑癌基因的缺失中同时存在 3例H -ras基因突变 ,两者的相关性为 4 2 9% .结论 :H -ras基因突变与P16抑癌基因缺失在膀胱移行细胞癌的发生中是否有密切相关性 。Objective: To investigate the mutations of oncogene H-ras and the deletion of antioncogene p16 in bladder transitional cell carcinoma. Methods: 31cases of bladder transitional cell carcinoma were detected by PCR-SSCP silver staining and duplex PCR. Results: The mutation ratio of H-ras was 38.7%. The deletion ratio of p16 was 22.6%. 7 cases with the deletion of 16 were shown to have 3 cases mutation of H-ras. Conclusion: It needs further study whether the mutation of H-ras and deletion of 16 was closely related to the occurrence of bladder carcinoma.

关 键 词：癌基因 H—ras 抑癌基因 P16 膀胱癌 病因 病理 

分 类 号：R737.14[医药卫生—肿瘤]